智通财经APP获悉，浙商证券发布研报称，马斯克旗下Neuralink首款产品Telepathy预计在今年量产，目 前超10000人申请体验。Neuralink现估值超90亿美金，公司愿景是增加沟通带宽，提高交流效率，联接 人脑与AI。在未来，假设交流带宽将成为生物与技术之间的瓶颈，普通人将通过脑机接口实现与AI的 交流和复杂机械的操控。政策端，我国脑计划十年规划(2021-2030)进入下半场关键落地期，脑机接口成 为新质生产力未来产业之一，迎政策东风。建议关注脑机接口与大模型、具身智能技术深入融合。 浙商证券主要观点如下： Neuralink的首款产品Telepathy(心灵感应)预计在今年量产，目前超10000人申请体验 Telepathy聚焦"大脑功能正常，但运动/交流通路断裂"的重症群体，例如脊髓损伤、渐冻症患者。量产 的三个重要条件——N1性能提升、手术安全性提升、成本降低：1)预计2026年N1设备电极数量从1000 个增加到3000个，提升神经信号的接收量。2)针对手术流程，未来将直接穿过包裹大脑的硬脑膜植入电 极线的技术，可降低手术的侵入性，减少风险，降低感染隐患。3)第二代设备将电极植入速度 ...

Market Overview - On February 9, the market opened high and closed higher, with the Shanghai Composite Index rising by 1.41%, the Shenzhen Component Index by 2.17%, and the ChiNext Index by 2.98%[3] - The total trading volume reached 2.27 trillion, an increase of approximately 110 billion compared to the previous trading day, indicating a market recovery[1] Sector Performance - Major sectors such as communication, media, electronics, and computers saw significant gains, particularly in AI applications where many stocks hit the daily limit up[1] - The top three sectors for net capital inflow were communication equipment, photovoltaic equipment, and semiconductors, while the sectors with the highest outflows were energy metals, oil service engineering, and agricultural chemicals[4] Investment Trends - The overall market remains cautious, with many stocks experiencing limit-up openings but also significant pullbacks, particularly in the space photovoltaic sector[1] - The current market characteristics suggest stabilization rather than aggressive buying, presenting a potential opportunity for early positioning[1] AI Sector Insights - AI application companies in the U.S. are showing high revenue growth, with domestic models like seedance 2.0 gaining traction, indicating a focus on AI applications in the market[2] Fundraising Activity - A total of 43 funds are set to be launched in February, with 33 being equity funds, accounting for nearly 80% of the total, indicating strong interest in new investment opportunities[13]

Group 1 - The core viewpoint of the news highlights a rebound in innovative pharmaceuticals, with the Guotai Innovation Drug ETF (589720) rising over 2% and attracting nearly 500 million yuan in funds over the past 10 days, currently leading its peers with a total size exceeding 1.5 billion yuan [1] - Recent industry dynamics focus on multinational collaborations and domestic innovations, exemplified by the strategic partnership between Innovent Biologics and Eli Lilly to advance global R&D in oncology and immunology, with Innovent receiving an upfront payment of 350 million USD and potential milestone payments of up to 8.5 billion USD [1] - Additionally, Carl Zeiss announced the launch of its Greater China headquarters project in Shanghai, aimed at integrating and upgrading its core functions in management, R&D, and production to strengthen its innovation network in China [1] Group 2 - Bohai Securities noted that at the 2026 JPM Healthcare Conference, numerous Chinese pharmaceutical companies showcased their latest research achievements, and there has been a surge in large-scale business development (BD) activities, indicating active collaboration with multinational corporations (MNCs) [2] - The report suggests monitoring companies that may experience a bottoming out of performance as earnings forecasts are disclosed, while also highlighting the rapid development of brain-computer interfaces and AI applications, which are expected to benefit consumer-oriented companies amid domestic demand recovery [2] - The industry faces several risks, including geopolitical tensions, product development failures, expanded centralized procurement leading to price pressures, intense competition causing price declines, and significant increases in raw material costs [2]

Group 1 - The core viewpoint of the article highlights the increasing investment and research activity in the brain-computer interface (BCI) industry in China, with a focus on key companies and patent trends [1][4][5] Group 2 - The research and development investment in the BCI industry by listed companies in China is steadily increasing from 2020 to 2024, indicating a strengthening of R&D efforts [1] - The number of patent applications in China's BCI industry showed a steady growth trend, peaking at 258 applications in 2021, followed by a decrease to 209 applications in 2024 [4] - Tianjin University is identified as the leading patent applicant in the BCI sector, with a total of 126 related patents, followed by South China University of Technology and Xi'an Jiaotong University with 80 and 78 patents respectively [5][7] - The most popular technology patents in the BCI industry are in the category of electrical digital data processing (G06F), with a total of 1,013 patents, followed by diagnostic and surgical technologies (A61B) with 712 patents, and specific computing models (G06N) with 313 patents [8]

分析师 1: 大家好，欢迎参加东北医药首席说脑机接口深度报告。现在有请主讲人开始发言，谢谢。 分析师 2: 好的，各位投资者晚上好，欢迎大家参加脑接口的这个行业深度报告。然后我们今天的这 个主要汇报的内容的话，主要有这个底下七个方面。然后实际上脑机接口这个赛道的话， 从今年年初，一直是属于非常热门的一个赛道话题。那么其实我们站在我们的角度的话， 我们理解脑机接口这个赛道的投资机会，它其实并不是一个情绪和主题催化的一个赛道， 它更多的话是反映的是一个产业的这个核心趋势。这个核心的产业趋势的话，一方面核心 的一个投资逻辑的话，也是跟我们看到的战略顶层的支持相关。 其实今天的话，也释放出了一个信号。就是我们国家最高领导人的话，在最新的这个科技 创新相关产业的视察过程中的话，也有相关脑机接口所在的一些研究院的领导出席。所以 脑科学战略的话，一直是属于非常，国家顶级的话，顶层非常关注的这样一个细分赛道。 那么整个脑机接口的话，我们从概念的领域，脑机接口我们可以把它划分成为这个按照它 这个脑电信号采集的这个位置的话，可以划分为这个侵入、半侵入和这个非侵入几大类。 然后这几大类的话，实际上的话，按照整个传感器的这个装，安装 ...

Core Viewpoint - The Hong Kong stock market showed strong performance in the healthcare sector, particularly in innovative drugs and medical companies, with significant gains observed in various stocks [1] Group 1: Market Performance - The Hong Kong stock market experienced fluctuations but ultimately strengthened, with notable performances in the innovative drug and medical sectors [1] - Stocks such as CSPC Pharmaceutical Group and Innovent Biologics rose over 6%, while others like Zai Lab and WuXi Biologics increased by more than 5% [1] - The Hong Kong Stock Connect Medical ETF (159506) saw a rise of over 3% during trading [1] Group 2: Industry Insights - At the J.P. Morgan Healthcare Conference held in January, global pharmaceutical companies disclosed advanced research pipelines and significant business development transactions, creating clear order expectations for the CXO industry [1] - The penetration of AI in healthcare is accelerating, with applications expanding from smart consultations to chronic disease management, leading to a reevaluation of the value of internet healthcare platforms like Alibaba Health and JD Health [1] - Analysts suggest that the current healthcare sector presents multiple investment opportunities, with the CXO industry benefiting from a recovery in overseas orders and domestic capacity clearance [1] - The medical device sector is supported by domestic equipment upgrade policies and overseas market expansion, with cutting-edge areas like brain-computer interfaces and AI imaging continuously catalyzing growth [1] - Internet healthcare is optimizing operational efficiency against the backdrop of deepening medical insurance payment reforms, leading to a clearer profitability growth trajectory [1] Group 3: ETF Information - The Hong Kong Stock Connect Medical ETF (159506) closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug and Healthcare Index (HSSCHI) [2] - The index composition emphasizes companies with high R&D expenditure and innovative drug business, ensuring that companies with the lowest average R&D to revenue ratio over the past two years are excluded [2] - This innovative focus aids investors in accurately capturing investment opportunities within the Hong Kong pharmaceutical sector [2]

| 4-685 | ਕੇ ਕਿ 名称 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 159567 | 跨 港股创新药ETF T+0 | 0.029 | 3.72% | | 159570 | 跨 港股通创新药ETF T+0 | 0.061 | 3.77% | | 520700 | 跨 港股通创新药ETF万家 T+0 | 0.059 | 3.72% | | 159286 | 時 港股通创新药ETF鹏华 T+0 | 0.031 | 3.72% | | 513780 | 跨 港股创新药50ETF T+0 | 0.060 | 3.65% | | 159297 | 跨 港股通创新药ETF南方 T+0 | 0.030 | 3.68% | | 159217 | 陪 港股通创新药ETF工银 T+0 | 0.048 | 3.66% | | 520970 | 0 1 1 6 4 | 0.032 | 3.61% | | 513120 | 跨 港股创新药ETF T+0 | 0.046 | 3.60% | | 520500 | 跨 恒生创新药ETF T+0 | 0.057 | 3.56% | 有分析指 ...

开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。 湘财证券研报表示，站在当前时点来看，医药行业受医保控费影响的预期已充分反映，多层次的支付体 系正在建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向。 低位埋伏港股医药机遇，借道ETF效率更高，高弹性，T+0。港股通创新药ETF（520880）及其场外联 接基金（025221），100%布局创新药研发类公司，前十大权重股占比超73%，龙头属性突出。港股通 医疗ETF华宝（159137），锚定医疗创新，囊括脑机接口、AI医疗、互联网药店等热点概念，同时覆盖 创新药全产业链龙头。 2月份以来，港股医药、医疗以一波强势连阳行情，持续修复失地。热门ETF方面，2月10日，港股通创 新药ETF（520880）、港股通医疗ETF（159137）早盘悉数涨逾2%，其中，港股通创新药ETF （520880）涨幅更是逼近3%。值得一提的是，自2月份以来的7个交易日，上述2只ETF双双 ...

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [2][6]. Core Insights - The medical device procurement scale is experiencing a partial decline due to high base effects, but there are opportunities in the surgical robot market [2]. - The report emphasizes that the ongoing implementation of equipment upgrade policies is expected to drive long-term procurement levels in the medical device sector, recommending companies that are likely to benefit from these policies [4]. - The report highlights that the four ministries jointly issued a notice in 2024 aiming for a more than 25% increase in medical equipment investment by 2027 compared to 2023, which is expected to enhance the configuration of high-end equipment to levels comparable to middle-income countries [6]. Summary by Sections Investment Recommendations - The report suggests maintaining an "Overweight" rating and recommends companies likely to benefit from the equipment upgrade policies, including Mindray Medical, United Imaging, Kaili Medical, Aohua Endoscopy, and Jingfeng Medical-B. It also suggests paying attention to MicroPort Scientific-B [6]. Monthly Procurement Data - In January 2026, the procurement scale for new devices showed a year-on-year decline: MR down 22.6%, CT down 25.6%, DR down 18.2%, ultrasound down 10.1%, while endoscopy grew by 1.1%, and surgical robots declined by 20.1%. Company-specific performance showed United Imaging MR down 36.5%, United Imaging CT up 8.5%, Mindray ultrasound up 10.9%, Kaili ultrasound down 14.8%, Kaili endoscopy up 55.4%, and Aohua endoscopy down 11.7% [6]. Policy Impact - The report discusses the release of a guideline by the National Healthcare Security Administration on January 20, 2026, which establishes a unified pricing project for surgical robots, expected to accelerate the penetration and application of robotic surgery technology [6].

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]